Strike two for Lilly's novel schizophrenia drug
This article was originally published in Scrip
The large Phase II study (HBBM) on its pipeline schizophrenia drug LY2140023 has yielded the worst possible outcome for Eli Lilly. The Lilly drug trial could not be separated from placebo at either one of two doses, and therefore missed its primary efficacy endpoint. Not only that, the active comparator in the trial, risperidone, a generic drug since 2003, did demonstrate efficacy at a statistically significant level. The latest failure - coupled with LY2140023's already uncertain efficacy profile - casts serious uncertainty over whether the drug will reach the market.
You may also be interested in...
In early 2018 Johnson & Johnson is expecting to announce the first data from its long-awaited pivotal clinical trial program for esketamine in treatment-resistant depression; a successful result will open a lucrative commercial opportunity for J&J and give the wider depression market a new direction for growth.
Alkermes’s announcement of positive findings in the FORWARD-5 trial of its treatment-resistant depression drug ALKS 5461 came as a surprise, given the past two Phase III trials disappointed, but if it can gain approval, the buprenorphine/samidorphan product could meet an unmet need.
Amgen revealed more data from the ENDEAVOR study that further demonstrate Kyprolis's (carfilzomib; Amgen/Ono Pharmaceutical) superiority to Velcade (bortezomib; Takeda/Johnson & Johnson) as a second-line treatment for relapsed multiple myeloma.